Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Post by LithLoveron Apr 04, 2021 4:49pm
302 Views
Post# 32935382

Should have been done in this order

Should have been done in this orderIt would have made a whole lot more sense if Tripp would have NR it in this order:

1) April 1:  Q4 2020 - Report $3 million in revenue and $7 million in the bank

2) First week of April - Aristotle is ready to go this is how you order x, y, z and these are some of the deals and partnerships we all ready have in place.

3) Next day.  To assist with patients who test positive we have alligned ourselves with a global leading oncology center with patented technologies a LOI has been signed

4) 2nd week of April:- a CC with shareholders 

5) May 17:  Q1 2021 results even better than Q4 

6) May 17: Annual meeting 
<< Previous
Bullboard Posts
Next >>